




Searching News Database: Cell Therapeutics
HSMN NewsFeed - 27 Dec 2022
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn(R)
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn(R)
HSMN NewsFeed - 8 Nov 2021
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs
HSMN NewsFeed - 18 Oct 2021
NeuExcell Therapeutics names Lori Gavrin as Chief Business and Strategy Officer
NeuExcell Therapeutics names Lori Gavrin as Chief Business and Strategy Officer
HSMN NewsFeed - 30 Aug 2021
NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth
NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth
HSMN NewsFeed - 10 Feb 2021
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
HSMN NewsFeed - 23 Nov 2020
BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND
BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND
HSMN NewsFeed - 17 Nov 2020
Celularity Announces Appointments of Chief Medical Officer and Senior Vice President of Regulatory Affairs
Celularity Announces Appointments of Chief Medical Officer and Senior Vice President of Regulatory Affairs
HSMN NewsFeed - 24 Jun 2020
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
HSMN NewsFeed - 1 Jun 2018
Fortuna Fix Announces Appointment of Madhavan Balachandran to Board of Directors
Fortuna Fix Announces Appointment of Madhavan Balachandran to Board of Directors
HSMN NewsFeed - 30 Apr 2018
Adicet Bio appoints Elizabeth "EJ" Read, M.D. as Chief Technology Officer
Adicet Bio appoints Elizabeth "EJ" Read, M.D. as Chief Technology Officer
HSMN NewsFeed - 13 Apr 2018
Cellenkos, Inc. Announces Alick Sun as Senior Vice President for Corporate and Business Development
Cellenkos, Inc. Announces Alick Sun as Senior Vice President for Corporate and Business Development
HSMN NewsFeed - 8 Mar 2018
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017
HSMN NewsFeed - 2 Nov 2017
BrainStorm Strengthens Executive Team: Appoints Eyal Rubin as Chief Financial Officer
BrainStorm Strengthens Executive Team: Appoints Eyal Rubin as Chief Financial Officer
HSMN NewsFeed - 17 Aug 2017
BlueRock Therapeutics Expands Toronto Presence with R&D and Manufacturing Hub, Appoints Key R&D Leadership
BlueRock Therapeutics Expands Toronto Presence with R&D and Manufacturing Hub, Appoints Key R&D Leadership
HSMN NewsFeed - 25 Mar 2014
BrainStorm and Massachusetts General Hospital Sign Definitive Agreement for ALS Clinical Trial
BrainStorm and Massachusetts General Hospital Sign Definitive Agreement for ALS Clinical Trial
HSMN NewsFeed - 30 Jan 2014
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
HSMN NewsFeed - 6 Jan 2014
PIXUVRI(R) (pixantrone) Receives Positive Final Appraisal Determination from NICE
PIXUVRI(R) (pixantrone) Receives Positive Final Appraisal Determination from NICE
HSMN NewsFeed - 2 Jan 2014
Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat
Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat
HSMN NewsFeed - 4 Dec 2013
Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI(R) (pixantrone) in Germany
Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI(R) (pixantrone) in Germany
HSMN NewsFeed - 15 Oct 2013
Second Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Second Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
HSMN NewsFeed - 19 Aug 2013
Market Access Granted in France for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Market Access Granted in France for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
HSMN NewsFeed - 8 Jul 2013
Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
HSMN NewsFeed - 28 Mar 2013
Stem Cell Therapeutics Provides Corporate Update on Acquisitions and Financing
Stem Cell Therapeutics Provides Corporate Update on Acquisitions and Financing
HSMN NewsFeed - 4 Feb 2013
Stem Cell Therapeutics Announces Agreement With Trillium Therapeutics Inc. for Merger
Stem Cell Therapeutics Announces Agreement With Trillium Therapeutics Inc. for Merger
HSMN NewsFeed - 28 Jan 2013
BrainStorm Cell Therapeutics Appoints Alon Natanson as Chief Executive Officer
BrainStorm Cell Therapeutics Appoints Alon Natanson as Chief Executive Officer
HSMN NewsFeed - 2 Oct 2012
Cell Therapeutics OPAXIOTM Receives Orphan Drug Designation for Malignant Brain Cancer from FDA
Cell Therapeutics OPAXIOTM Receives Orphan Drug Designation for Malignant Brain Cancer from FDA
HSMN NewsFeed - 31 May 2012
Cell Therapeutics' Pixuvri(R) Phase 3 Clinical Trial Results Published in The Lancet Oncology
Cell Therapeutics' Pixuvri(R) Phase 3 Clinical Trial Results Published in The Lancet Oncology
HSMN NewsFeed - 6 Mar 2012
Islet Sciences Names Dr. George J. Todaro and Dr. Jerry L. Nader to Board of Directors
Islet Sciences Names Dr. George J. Todaro and Dr. Jerry L. Nader to Board of Directors
HSMN NewsFeed - 30 Jan 2012
Cell Therapeutics Withdraws New Drug Application for Pixuvri™ and Plans to Resubmit in 2012
Cell Therapeutics Withdraws New Drug Application for Pixuvri™ and Plans to Resubmit in 2012
HSMN NewsFeed - 24 Jan 2011
BrainStorm Appoints Dr. Adrian Harel as Chief Operating Officer and Acting Chief Executive Officer
BrainStorm Appoints Dr. Adrian Harel as Chief Operating Officer and Acting Chief Executive Officer
HSMN NewsFeed - 17 Nov 2010
European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri
European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri
HSMN NewsFeed - 17 Jun 2010
Bayer and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
Bayer and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
HSMN NewsFeed - 24 Aug 2009
BrainStorm Cell Therapeutics Secures Funding to Reach Clinical Trials for ALS
BrainStorm Cell Therapeutics Secures Funding to Reach Clinical Trials for ALS
HSMN NewsFeed - 7 Jul 2009
OncoMed Pharmaceuticals Appoints Sunil Patel Senior Vice President, Corporate Development
OncoMed Pharmaceuticals Appoints Sunil Patel Senior Vice President, Corporate Development
HSMN NewsFeed - 27 Jan 2009
Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
HSMN NewsFeed - 11 Nov 2008
Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
HSMN NewsFeed - 18 Aug 2008
Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
HSMN NewsFeed - 5 May 2008
European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics' Lung Cancer Drug
European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics' Lung Cancer Drug
HSMN NewsFeed - 23 Apr 2008
Stem Cell Therapeutics Corp. Receives "May Proceed" From FDA for Its Phase IIb Clinical Stroke Trial and IND
Stem Cell Therapeutics Corp. Receives "May Proceed" From FDA for Its Phase IIb Clinical Stroke Trial and IND
HSMN NewsFeed - 4 Mar 2008
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
HSMN NewsFeed - 20 Feb 2008
Stem Cell Therapeutics Announces Favorable Results From the Phase IIa BETAS Stroke Trial
Stem Cell Therapeutics Announces Favorable Results From the Phase IIa BETAS Stroke Trial
HSMN NewsFeed - 12 Nov 2007
BrainStorm Cell Therapeutics Secures Significant Equity Financing and Raises Research Budget
BrainStorm Cell Therapeutics Secures Significant Equity Financing and Raises Research Budget
HSMN NewsFeed - 8 Nov 2007
Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
HSMN NewsFeed - 15 Oct 2007
Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
HSMN NewsFeed - 8 Oct 2007
BrainStorm on the Verge of a Breakthrough Towards Developing a Cure for Lou Gehrig's Disease
BrainStorm on the Verge of a Breakthrough Towards Developing a Cure for Lou Gehrig's Disease
HSMN NewsFeed - 11 Jul 2007
StemCyte Appoints Robert Dickey IV as Senior Vice President and Chief Financial Officer
StemCyte Appoints Robert Dickey IV as Senior Vice President and Chief Financial Officer
HSMN NewsFeed - 14 May 2007
Former Immunex Management Team Chosen to Head-Up CTI Subsidiary Aequus BioPharma, Inc.
Former Immunex Management Team Chosen to Head-Up CTI Subsidiary Aequus BioPharma, Inc.
HSMN NewsFeed - 7 May 2007
Bill Cadwallader Joins Velcura Therapeutics, Inc. as Executive Vice President of Corporate Development
Bill Cadwallader Joins Velcura Therapeutics, Inc. as Executive Vice President of Corporate Development
HSMN NewsFeed - 7 May 2007
Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
HSMN NewsFeed - 12 Dec 2006
Northern Therapeutics and MaxCyte Initiate Landmark Engineered Cell Therapy Trial for Fatal Lung Disease
Northern Therapeutics and MaxCyte Initiate Landmark Engineered Cell Therapy Trial for Fatal Lung Disease
HSMN NewsFeed - 12 Dec 2006
Cell Therapeutics, Inc. (CTI) Announces Pixantrone Combination Regimen Produces High Response Rates
Cell Therapeutics, Inc. (CTI) Announces Pixantrone Combination Regimen Produces High Response Rates
HSMN NewsFeed - 2 Nov 2006
Gamida Cell's StemEx(R) Registration Study Receives Special Protocol Assessment from the FDA
Gamida Cell's StemEx(R) Registration Study Receives Special Protocol Assessment from the FDA
HSMN NewsFeed - 26 Oct 2006
NeoStem, Inc. Appoints Julio C. Guerra, MD, ABP, as Director of Sales and Marketing
NeoStem, Inc. Appoints Julio C. Guerra, MD, ABP, as Director of Sales and Marketing
HSMN NewsFeed - 8 Aug 2006
Cell Therapeutics, Inc. (CTI) Announces Encouraging Pixantrone Phase III Interim Data
Cell Therapeutics, Inc. (CTI) Announces Encouraging Pixantrone Phase III Interim Data
HSMN NewsFeed - 4 Jun 2006
Data from XYOTAX(TM) STELLAR Trials Presented at 2006 Meeting of American Society of Clinical Oncology
Data from XYOTAX(TM) STELLAR Trials Presented at 2006 Meeting of American Society of Clinical Oncology
HSMN NewsFeed - 1 Jun 2006
Cell Therapeutics, Inc. (CTI) and FDA Agree on NDA Filing Strategy for XYOTAX(TM)
Cell Therapeutics, Inc. (CTI) and FDA Agree on NDA Filing Strategy for XYOTAX(TM)
HSMN NewsFeed - 1 May 2006
World-Renowned Safety Consultant Joy A. Cavagnaro Joins BrainStorm Cell Therapeutics
World-Renowned Safety Consultant Joy A. Cavagnaro Joins BrainStorm Cell Therapeutics
HSMN NewsFeed - 10 Apr 2006
StemCells, Inc. Names Elizabeth Leininger Vice President, Regulatory Affairs and Quality Assurance
StemCells, Inc. Names Elizabeth Leininger Vice President, Regulatory Affairs and Quality Assurance
HSMN NewsFeed - 20 Jan 2006
Stem Cell Therapeutics Corp. Announces Selected Upcoming Development Milestones
Stem Cell Therapeutics Corp. Announces Selected Upcoming Development Milestones
Additional items found! 96

Members Archive contains
96 additional stories matching:
Cell Therapeutics
(Password required)
Cell Therapeutics
(Password required)